Mitchell J R
Department of Medicine, University Hospital, Nottingham, England.
Schweiz Med Wochenschr. 1990 Mar 17;120(11):359-64.
There is no doubt about the association between coronary heart disease (CHD) and smoking, high serum cholesterol and high blood pressure, but association does not mean causation. To prove causation we must mount intervention trials and show that changing a risk marker changes total mortality: a) Trials of dietary reduction of serum lipids: The US Veterans dietary study and the North Karelia project showed no significant reduction in total mortality, nor did the Multiple Risk Factor Intervention Trial (MRFIT) or the WHO "paired-factories" Collaborative Group Study, where other risk factors were also being corrected. In the latter study there was a barely significant reduction in non-fatal CHD but fatal CHD, like total mortality was unchanged. b) Trials of lipid-lowering drugs: The first large-scale study, using clofibrate, showed an increase in total mortality; the screening of 500,000 men and the comparison of cholestyramine with placebo for the top 5% of lipid levels resulted in 68 deaths on the active resin and 71 on placebo. Less expensive measures (alcohol testing; safer roads) could surely do more good to half a million men? These 3 lives "saved" were "lost" in the Helsinki gemfibrozil study where there were 45 deaths in the active group and 42 in the placebo group. c) Effect of blood-pressure reduction. The assumption that reducing a risk marker will reduce CHD was challenged by the massive MRC Mild-to-Moderate Hypertension trial which showed no significant effect of treatment on CHD, CHD death or total mortality, even though stroke mortality was modestly reduced.(ABSTRACT TRUNCATED AT 250 WORDS)
冠心病(CHD)与吸烟、高血清胆固醇和高血压之间的关联是毋庸置疑的,但关联并不意味着因果关系。为了证明因果关系,我们必须进行干预试验,并表明改变一个风险指标会改变总死亡率:a)降低血清脂质的饮食试验:美国退伍军人饮食研究和北卡累利阿项目均未显示总死亡率有显著降低,多重危险因素干预试验(MRFIT)或世界卫生组织“配对工厂”合作组研究也未显示,后者在纠正其他危险因素时,非致命性冠心病仅有微弱的显著降低,但致命性冠心病和总死亡率均未改变。b)降血脂药物试验:第一项使用氯贝丁酯的大规模研究显示总死亡率增加;对50万名男性进行筛查,并将胆酸螯合剂与安慰剂用于脂质水平最高的5%人群进行比较,使用活性树脂的有68人死亡,使用安慰剂的有71人死亡。成本更低的措施(酒精检测;更安全的道路)肯定能为50万男性带来更多益处吧?在赫尔辛基吉非贝齐研究中,这“挽救”的3条生命“消失”了,活性组有45人死亡,安慰剂组有42人死亡。c)降低血压的效果。大规模的医学研究委员会轻度至中度高血压试验对降低一个风险指标就能降低冠心病这一假设提出了挑战,该试验表明治疗对冠心病、冠心病死亡或总死亡率均无显著影响,尽管中风死亡率略有降低。(摘要截选至250词)